pemphigus vulgaris pipeline insight

DelveInsight’s, “Pemphigus Vulgaris - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pemphigus Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Pemphigus Vulgaris: Understanding

Pemphigus Vulgaris: Overview

Pemphigus vulgaris (PV) is a rare, chronic autoimmune blistering disorder that primarily affects the skin and mucous membranes, characterized by the loss of cell-to-cell adhesion in the epithelium—a process known as acantholysis. The disease results from the production of autoantibodies against desmoglein 3 (and sometimes desmoglein 1), proteins essential for maintaining the integrity of epithelial cell junctions. Clinically, PV presents with painful, flaccid blisters and erosions, especially in the oral cavity, which often precede skin involvement. Though historically believed to be infectious, PV is now recognized as non-contagious, with various potential triggers such as certain medications, stress, and coexisting autoimmune conditions playing a role in its onset. First described in 1788, PV remains a serious condition requiring early diagnosis and long-term immunosuppressive therapy to manage symptoms and prevent complications.

 

Pemphigus vulgaris typically presents with a range of painful and often debilitating symptoms, most notably the formation of flaccid, fluid-filled blisters on the skin and mucous membranes. These blisters are fragile and prone to rupturing, leading to open sores that may ooze, crust over, and become secondarily infected. One of the earliest and most common manifestations is the presence of painful oral lesions, which can interfere with speaking, eating, and drinking, often resulting in weight loss and nutritional deficiencies. As the disease progresses, widespread erosions and ulcers may develop across various mucosal surfaces, including the mouth, nose, throat, eyes, genitals, and esophagus, causing additional complications such as hoarseness, dysphagia, and poor oral intake. The skin becomes extremely fragile and may peel or slough off with minimal friction, a clinical feature known as Nikolsky’s sign. Due to the chronic nature and severity of these symptoms, pemphigus vulgaris significantly impacts a patient’s quality of life and requires prompt and effective medical management.

 

Pemphigus vulgaris (PV) is caused by a type II hypersensitivity reaction in which IgG autoantibodies target desmoglein 3 (Dsg3) and sometimes desmoglein 1 (Dsg1), key adhesion proteins in desmosomes that maintain cell-to-cell cohesion in the skin and mucous membranes. The binding of these autoantibodies disrupts desmosomal function through mechanisms such as steric hindrance, signaling pathway activation, and desmosome depletion, leading to acantholysis—the separation of keratinocytes—and the formation of fragile blisters. Dsg3 is predominantly found in mucous membranes, while Dsg1 is more superficial and cutaneous, explaining the distribution of lesions in PV. Animal studies support the role of these antibodies, and newer theories like the desmoglein nonassembly depletion hypothesis suggest that impaired desmosome formation also contributes to disease progression.

 

The treatment of pemphigus vulgaris (PV) begins with systemic corticosteroids, which are the first-line therapy, especially for mild cases. In moderate to severe disease, corticosteroids are combined with anti-CD20 monoclonal antibodies like rituximab, which targets B cells and reduces autoantibody production. Second-line treatments include steroid-sparing agents such as azathioprine and mycophenolate mofetil to help minimize long-term steroid use. Third-line options may involve IVIG, cyclophosphamide, methotrexate, or dapsone. Emerging therapies focus on newer monoclonal antibodies and agents targeting B-cell and cytokine pathways, though their high cost limits widespread use.

 

"Pemphigus Vulgaris- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pemphigus Vulgaris pipeline landscape is provided which includes the disease overview and Pemphigus Vulgaris treatment guidelines. The assessment part of the report embraces, in depth Pemphigus Vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pemphigus Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pemphigus Vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Pemphigus Vulgaris.

 

Pemphigus Vulgaris Emerging Drugs Chapters

This segment of the Pemphigus Vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Pemphigus Vulgaris Emerging Drugs

• CABA-201: Cabaletta Bio

CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy for patients with autoimmune diseases where B cells contribute to the initiation and/or maintenance of disease. Following a one-time infusion, CABA-201 is designed to transiently and completely deplete all CD19-positive cells. This approach has the potential to reset the immune system and result in compelling clinical responses without chronic therapy requirements in patients. Cabaletta is currently evaluating CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical development program which includes multiple disease-specific, company-sponsored clinical trials across growing portfolios of autoimmune diseases in a broad range of therapeutic areas, including rheumatology, neurology and dermatology. Currently, the drug is in Phase I/II stage of its development for the treatment of Pemphigus Vulgaris.

 

• AlloNK: Artiva Biotherapeutics, Inc.

AlloNK is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the ADCC effect of mAbs to drive B-cell depletion. AlloNK, as a non-genetically modified, non-targeted NK cell, is designed to utilize a mAb or NK engager for targeting, and therefore can be used in different combinations against different therapeutic targets. AlloNK is currently in clinical trials for treatment of systemic lupus erythematosus (SLE) for patients with or without lupus nephritis and in a basket investigator-initiated trial (IIT) in multiple autoimmune indications. In addition, AlloNK is being evaluated for the treatment of non-Hodgkin lymphoma, as well as in combination with Affimed’s innate cell engager acimtamig for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Currently, the drug is in Phase I stage of its development for the treatment of Pemphigus Vulgaris.

Further product details are provided in the report……..

 

Pemphigus Vulgaris: Therapeutic Assessment

This segment of the report provides insights about the different Pemphigus Vulgaris drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Pemphigus Vulgaris

There are approx. 3+ key companies which are developing the therapies for Pemphigus Vulgaris. The companies which have their Pemphigus Vulgaris drug candidates in the most advanced stage, i.e. Phase I/II include, Cabaletta Bio.

 

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Pemphigus Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Pemphigus Vulgaris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Pemphigus Vulgaris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pemphigus Vulgaris drugs.

 

Pemphigus Vulgaris Report Insights

• Pemphigus Vulgaris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pemphigus Vulgaris Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pemphigus Vulgaris drugs?
• How many Pemphigus Vulgaris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pemphigus Vulgaris?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pemphigus Vulgaris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pemphigus Vulgaris and their status?
• What are the key designations that have been granted to the emerging drugs?